trial · primary record
Adagrasib
Advanced Non-Small Cell Lung Cancer
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 626 |
| Primary completion | 2029-10-31 |
| Primary endpoint | Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC. |
| Registry ID | NCT04613596 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:37.355Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04613596
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.